A new biotech that is using CRISPR gene-editing technology to discover drugs for cancer and autoimmune diseases is opening a lab in Branford after raising $35 million earlier this year.
The company, EvolveImmune Therapeutics, is helmed by veteran Connecticut venture capitalist Stephen Bloch, MD, and has already attracted early-stage backing from some large pharmaceutical firms.